Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,818 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXTEND Clear all
Terminated Phase 1 Interventional

A Phase 1 Study of ADI-001 in B Cell Malignancies

NCT04735471
View directory record Official record
Conditions
Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Interventions
ADI-001, Fludarabine, Cyclophosphamide
Genetic · Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Stanford, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion

NCT01368198
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Balance Lubricating Eye Drops, OPTIVE™
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 18, 2026, 5:07 AM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

NCT07161700
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 66 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Chino, California • Garden Grove, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 5:07 AM EDT
Not yet recruiting Phase 4 Interventional

Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion

NCT07873632
View directory record Official record
Conditions
Bronchitis, Bronchitis, Chronic
Interventions
Glycerol Guiacolate, SOC (Standard of care)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

Impact of Oral Antibiotic Treatment on C. Difficile

NCT02057198
View directory record Official record
Conditions
C. Difficile, Diarrhea, Enterocolitis
Interventions
Fidaxomicin, Metronidazole, Vancomycin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 18, 2026, 5:07 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT01156051
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
Interventions
Guanfacine extended-release tablets, Placebo comparator
Drug
Lead sponsor
Children's Specialized Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Hamilton, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Creatine Safety & Tolerability in Huntington's Disease

NCT01412151
View directory record Official record
Conditions
Huntington's Disease (HD)
Interventions
Creatine monohydrate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treating Comorbid Depression During Care Transitions Using Relational Agents

NCT02845102
View directory record Official record
Conditions
Chronic Illness, Chronic Pain, Depression, Comorbid Depression
Interventions
Pre-Post Feasibility
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Timing, Eating and Activity Measurement Study

NCT04992611
View directory record Official record
Conditions
Sleep, Circadian Rhythm Disorders, Dietary Habits
Interventions
Sleep Extension (Early), Sleep Extension (Late)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 18 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional

RCT of an Integrative Intervention for Non-Treatment-Seeking Meth Users

NCT01926184
View directory record Official record
Conditions
HIV/AIDS, Stimulant Use Disorders
Interventions
Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS), Contingency Management (CM)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Caregiver Protocol for Remotely Improving, Monitoring, and Extending Quality of Life

NCT05379933
View directory record Official record
Conditions
Stress, Quality of Life, Sleep Disturbance
Interventions
Remote health coaching to improve self-care behaviors
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 18, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalation PfSPZ-CVac

NCT03083847
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 18, 2026, 5:07 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT04000009
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Garden Grove, California • Glendale, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 18, 2026, 5:07 AM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

NCT06375993
View directory record Official record
Conditions
Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions
ADI-001, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Redwood City, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 18, 2026, 5:07 AM EDT
Terminated No phase listed Observational

Multi-Center Study to Evaluate the ConforMIS iUni Knee Implant

NCT01117571
View directory record Official record
Conditions
Osteoarthritis
Interventions
iUni® Unicompartmental Knee Resurfacing Device
Device
Lead sponsor
Restor3D
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
8
States / cities
Little Rock, Arkansas • La Quinta, California • Monterey, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

NCT02485899
View directory record Official record
Conditions
Jansky-Bielschowsky Disease, Batten Disease, Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2, CLN2 Disease, CLN2 Disorder
Interventions
BMN 190, Intracerebroventricular (ICV) access device
Biological · Device
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
3 Years to 16 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 18, 2026, 5:07 AM EDT
Terminated Not applicable Interventional Results available

Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer

NCT04827732
View directory record Official record
Conditions
Recurrent Rectal Cancer
Interventions
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy, MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Radiation · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 18, 2026, 5:07 AM EDT
Not listed Phase 4 Interventional

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

NCT05863221
View directory record Official record
Conditions
Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions
ZYNRELEF 200Mg-6Mg Extended-Release Solution
Drug
Lead sponsor
Dr. Yannis Raftopoulos
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Holyoke, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta

NCT00181714
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 18, 2026, 5:07 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

NCT00364832
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
6
States / cities
Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

NCT02954887
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 18, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

NCT03920293
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Ravulizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 18, 2026, 5:07 AM EDT